aspirin plus P2Y12 antagonist

DRUG2 trials

Sponsors

Samsung Medical Center, Gangnam Severance Hospital

Conditions

Coronary Artery Disease

Unknown Phase

Comparison Between P2Y12 Antagonist Monotherapy and Dual Antiplatelet Therapy After DES

Samsung Medical CenterCoronary Artery Disease

Start: 2014-03-18End: 2020-07-07Updated: 2019-01-31

Short-term Dual Antiplatelet Therapy After Deployment of Bioabsorbable Polymer Everolimus-eluting Stent

CompletedNCT03447379

Gangnam Severance HospitalCoronary Artery Disease

Start: 2017-12-15End: 2022-08-17Updated: 2025-03-12

Related Papers

P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Deployment of a Drug-Eluting Stent

JAMA Network Open2024-03-0716 citations

The Association of CHADS-P2A2RC Risk Score With Clinical Outcomes in Patients Taking P2Y12 Inhibitor Monotherapy After 3 Months of Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention

Korean Circulation Journal2024-01-011 citations

Sex-Based Outcomes of P2Y12 Inhibitor Monotherapy After Three Months of Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention.

2023-11-205 citations

Long-term Effects of P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention

JAMA Cardiology2022-09-2813 citations

Clopidogrel monotherapy in patients with and without on-treatment high platelet reactivity: a SMART-CHOICE substudy

EuroIntervention2021-12-019 citations

P2Y12 inhibitor monotherapy after coronary stenting according to type of P2Y12 inhibitor

Heart2021-03-237 citations

Safety of 3‐Month Dual Antiplatelet Therapy After Implantation of Ultrathin Sirolimus‐Eluting Stents With Biodegradable Polymer (Orsiro): Results From the SMART‐CHOICE Trial

Journal of the American Heart Association2020-12-218 citations

Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention

JAMA2019-06-25587 citations